Suresh Sakkarai Ramalingam MD FACP, FASCO

Oncology•Atlanta, GA

Hematologic Oncology, Thoracic Cancer

Executive Director, Winship Cancer Institute of Emory University

Join to View Full Profile

1365 Clifton Rd NE# WinshipAtlanta, GA 30322
Phone+1 404-778-5961
Fax+1 404-778-5520

Education & Training

UPMC Medical EducationFellowship, Hematology and Medical Oncology, 2000 - 2003
Wayne State University School of MedicineResidency, Internal Medicine, 1993 - 1996
Kilpauk Medical CollegeClass of 1992

Certifications & Licensure

GA State Medical License 2007 - 2025
PA State Medical License 2000 - 2008
MI State Medical License 1995 - 2002
American Board of Internal Medicine Medical Oncology

Clinical Trials

17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor Start of enrollment: 2004 May 01
Completed
Phase 1
Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer Start of enrollment: 2005 Oct 13
Completed
Phase 2
Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer Start of enrollment: 2005 Jun 01
Completed
Phase 2
Vorinostat, Paclitaxel, and Carboplatin in Treating Patients With Advanced or Refractory Solid Tumors Start of enrollment: 2005 Jul 01
Completed
Phase 1
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jul 19
COMPLETED
PHASE3
PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery Start of enrollment: 2006 Jun 01
Completed
Phase 2
Trial of RAD001 in Patients With Operable Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2006 Nov 01
Completed
Phase 1
Phase I/II Trial of RAD001 Plus Docetaxel in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer Start of enrollment: 2006 Nov 01
Terminated
Phase 1, Phase 2
Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Start of enrollment: 2007 May 01
Completed
Phase 2
Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction Start of enrollment: 2007 Jun 01
Completed
Phase 1
Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer Start of enrollment: 2007 Sep 01
Completed
Phase 1
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Start of enrollment: 2010 Oct 25
Completed
Phase 3
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Start of enrollment: 2011 Jun 20
ACTIVE_NOT_RECRUITING
PHASE1
A Phase I Study of OSI-906 in Combination With Pemetrexed in Advanced Solid Tumor Malignancies Start of enrollment: 2012 May 01
Withdrawn
Phase 1
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer Start of enrollment: 2013 Sep 01
Completed
Phase 2
A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA) Start of enrollment: 2018 Jul 19
ACTIVE_NOT_RECRUITING
PHASE3
Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer Start of enrollment: 2019 Feb 12
Completed
Phase 1, Phase 2
GEN1046 Safety Trial in Patients With Malignant Solid Tumors Start of enrollment: 2019 May 14
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery Start of enrollment: 2019 Oct 08
COMPLETED
PHASE3
Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2022 Nov 01
RECRUITING
EARLY_PHASE1
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC‒A Brief Report.
Gregory J Riely, Myung-Ju Ahn, Jeffrey M Clarke, Ibiayi Dagogo-Jack, Raymond Esper
Journal of Thoracic Oncology. 2025-06-04
Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic Non-small Cell Lung Cancer Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemo...
Solange Peters, Meredith M Regan, Luis G Paz-Ares, Martin Reck, Hossein Borghaei
Journal of Thoracic Oncology. 2025-06-03
Neoadjuvant Osimertinib: A Step Ahead or Just a Step?
Suresh S Ramalingam, Thomas E Stinchcombe
Journal of Clinical Oncology. 2025-06-02

Journal Articles

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
David S Hong, Marwan G Fakih, Gregory A Durm, Geoffrey I Shapiro, Gerald S Falchook, Adrian Sacher, Crystal S Denlinger, John C Krauss, Andrew L Coveler, Suresh S Rama..., The New England Journal of Medicine
Concurrent Chemoradiotherapy with Weekly Versus Triweekly Cisplatin in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Comparative Analysis
Rathi Pillai, Fadlo R Khuri, Nabil F Saba, Conor Steuer, Suchita Pakkala, Kristin Higgins, Jonathan J Beitler, Suresh S Ramalingam, Brandon Twardy, Kelly Schrapp, Taof..., Head & Neck
Targeted Sequencing and Intracranial Outcomes of Patients with Lung Adenocarcinoma Brain Metastases Treated with Radiotherapy
Gabriel L Sica, Matthew J Ferris, Walter J Curran, Shannon Kahn, Suresh S Ramalingam, Pretesh R Patel, Rathi N Pillai, Robert H Press, Jim Zhong, Conor E Steuer, Taofe..., Cancer
Predictive Biomarkers for Response to EGFR-Directed Monoclonal Antibodies for Advanced Squamous Cell Lung Cancer
D R Spigel, E S Kim, S S Ramalingam, M A Socinski, C Obasaju, C J Langer, R B Natale, P D Bonomi, H Wakelee, Annals of Oncology
Join now to see all

Lectures

ECOG-ACRIN 5508: Pemetrexed, bevacizumab or the combination as maintenance therapy for advanced non-squamous NSCLC.
2019 ASCO Annual Meeting - 6/1/2019

Other

How Immunotherapy Is Dramatically Changing Treatment for Non-Small and Small Cell Lung Cancer
Suresh Ramalingam, MD, Op-Med
https://www.doximity.com/articles/35d1fb9e-f71f-4645-839f-870e7b27ebe0
UpToDate, Wolters Kluwer Health - 2012-10-04

Authored Content

How Immunotherapy Is Dramatically Changing Treatment for Non-Small and Small Cell Lung CancerOctober 2018

Press Mentions

“Indian American Cancer Scientists Honored with Prestigious Awards for Groundbreaking Discoveries”May 9th, 2025
Less Is More: The Case for De-Escalation Strategies in Lung Cancer ManagementApril 23rd, 2025
Osimertinib OS Benefit Persists Among Patients with EGFR+ NSCLCMarch 31st, 2025
Join now to see all

Grant Support

Administrative Supplement: Assessing and Enhancing Survivorship CareEMORY UNIVERSITY2009–2028
Administrative Supplement: Assessing and Enhancing Survivorship CareEMORY UNIVERSITY2009–2028
Winship Cancer Institute Cancer Center Support GrantEMORY UNIVERSITY2009–2028
Administrative Supplement: Assessing and Enhancing Survivorship CareEMORY UNIVERSITY2009–2028
Winship Cancer Institute Cancer Center Support GrantEMORY UNIVERSITY2009–2028
Administrative Supplement: Assessing and Enhancing Survivorship CareEMORY UNIVERSITY2009–2028
Winship Cancer Institute Cancer Center Support GrantEMORY UNIVERSITY2009–2028
Winship Cancer Institute Cancer Center Support GrantEMORY UNIVERSITY2009–2028
Deciphering LKB1-associated immunotherapy resistance in lung adenocarcinoma (LUAD)EMORY UNIVERSITY2022–2027
Administrative Supplement: Interim Funding for Emory Lung Cancer SPOREEMORY UNIVERSITY2019–2025
Emory University Lung Cancer SPOREEMORY UNIVERSITY2019–2025
Administrative Supplement: Interim Funding for Emory Lung Cancer SPOREEMORY UNIVERSITY2019–2025
Administrative Supplement: Interim Funding for Emory Lung Cancer SPOREEMORY UNIVERSITY2019–2025
Administrative Supplement: Interim Funding for Emory Lung Cancer SPOREEMORY UNIVERSITY2019–2025
Administrative Supplement: Interim Funding for Emory Lung Cancer SPOREEMORY UNIVERSITY2019–2025
Emory University Lung Cancer SPOREEMORY UNIVERSITY2019–2025
Emory Clinical Oncology Career Development Award K12 ProgramEMORY UNIVERSITY2019–2025